MedTrace Logo

Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

NCT03978884 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-09-03

No results posted yet for this study

Summary

To study antihypertensive efficacy of 12 weeks of Losartan based therapy Resilo (Losartan) and Resilo-H (Losartan+ Hydrochlorothiazide) in uncontrolled hypertensive and diabetic hypertensive patients.

Conditions

Interventions

DRUG

Losartan 50Mg Tab

Take 1 tab daily

DRUG

Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET

Take 1 tab daily

DRUG

Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET

Take 1 tab daily

DRUG

Amlodipine 5mg

Take 1 tablet daily

Sponsors & Collaborators

  • Caribbean College of Family Physicians

    collaborator UNKNOWN

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • Marvin Reid · University of the West Indies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-05-31
Completion
2020-12-31

Countries

  • Jamaica

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03978884 on ClinicalTrials.gov